Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice 18-Month Clinical and 9-Month Angiographic Outcomes

被引:71
作者
Han, Yaling [1 ]
Jing, Quanmin [1 ]
Xu, Bo [2 ,3 ]
Yang, Lixia [4 ]
Liu, Huiliang [5 ]
Shang, Xiaoming [6 ]
Jiang, Tieming [7 ]
Li, Zhanquan [8 ]
Zhang, Hua [9 ]
Li, Hui [10 ]
Qiu, Jian [11 ]
Liu, Yingfeng [12 ]
Li, Yi [1 ]
Chen, Xuezhi [1 ]
Gao, Runlin [2 ,3 ]
机构
[1] Shenyang No Hosp, Dept Cardiol, Shenyang 110016, Peoples R China
[2] Cardiovasc Inst, Beijing, Peoples R China
[3] Fuwai Hosp, Beijing, Peoples R China
[4] Kunming Gen Hosp Chengdu Mil Reg, Kunming, Peoples R China
[5] Gen Hosp Armed Police Forces, Beijing, Peoples R China
[6] Tangshan Gongren Hosp, Tangshan, Peoples R China
[7] Affiliated Hosp, Chinese Peoples Armed Police Forces Med Coll, Tianjin, Peoples R China
[8] Peoples Hosp Liaoning Prov, Shenyang, Peoples R China
[9] Shanxi Prov Corps Hosp Chinese Peoples Armed Poli, Xian, Peoples R China
[10] Daqing Oilfields Gen Hosp, Daqing, Peoples R China
[11] Guangzhou Army Gen Hosp, Guangzhou, Guangdong, Peoples R China
[12] So Med Univ, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China
关键词
drug-eluting stents; sirolimus; biodegradable polymer; coronary heart disease; CORONARY-THROMBOSIS; IMPLANTATION; LESIONS; TRIALS; HYPERSENSITIVITY; DISCONTINUATION; CARDIOLOGY; ARTERIES; EVENTS;
D O I
10.1016/j.jcin.2008.12.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to evaluate the safety and efficacy of a biodegradable polymer-coated sirolimus-eluting stent (Excel, JW Medical System, Weihai, China) with 6-month dual antiplatelet therapy in daily practice. Background It has been hypothesized that persistent presence of polymer may compromise the safety of drug-eluting stents, and that therefore biodegradable polymer coatings might reduce late adverse events. Methods Between June and November 2006, 2,077 patients, exclusively treated with Excel stents at 59 centers from 4 countries, were enrolled in this prospective, multicenter registry. Recommended antiplatelet regimen included clopidogrel and aspirin for 6 months followed by chronic aspirin therapy. Results The average duration of clopidogrel treatment was 199.8 +/- 52.7 days and 80.5% of discharged patients discontinued clopidogrel at 6 months. The cumulative rates of major adverse cardiac events were 0.9% at 30 days, 2.7% at 1 year, and 3.1% at 18 months. Overall rate of stent thrombosis was 0.87% at 18 months. The rates of acute, subacute, late, and very late stent thrombosis were 0.1%, 0.38%, 0.34%, and 0.05%, respectively. Angiographic follow-up, performed in 974 (31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss of 0.21 +/- 0.39 mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment. Conclusions This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting. (Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent [CREATE]; NCT00331578) (J Am Coll Cardiol Intv 2009;2:303-9) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:303 / 309
页数:7
相关论文
共 36 条
[31]   Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries [J].
vanderGiessen, WJ ;
Lincoff, AM ;
Schwartz, RS ;
vanBeusekom, HMM ;
Serruys, PW ;
Holmes, DR ;
Ellis, SG ;
Topol, EJ .
CIRCULATION, 1996, 94 (07) :1690-1697
[32]   Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? [J].
Virmani, R ;
Guagliumi, G ;
Farb, A ;
Musumeci, G ;
Grieco, N ;
Motta, T ;
Mihalcsik, L ;
Tespili, M ;
Valsecchi, O ;
Kolodgie, FD .
CIRCULATION, 2004, 109 (06) :701-705
[33]   Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans [J].
Virmani, R ;
Liistro, F ;
Stankovic, G ;
Di Mario, C ;
Montorfano, M ;
Farb, A ;
Kolodgie, FD ;
Colombo, A .
CIRCULATION, 2002, 106 (21) :2649-2651
[34]   Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design [J].
Wessely, Rainer ;
Kastrati, Adnan ;
Mehilli, Julinda ;
Dibra, Alban ;
Pache, Juergen ;
Schoemig, Albert .
EUROPEAN HEART JOURNAL, 2007, 28 (22) :2720-2725
[35]   Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization [J].
Windecker, S ;
Remondino, A ;
Eberli, FR ;
Jüni, P ;
Räber, L ;
Wenaweser, P ;
Togni, M ;
Billinger, M ;
Tüller, D ;
Seiler, C ;
Roffi, M ;
Corti, R ;
Sütsch, G ;
Maier, W ;
Lüscher, T ;
Hess, OM ;
Egger, M ;
Meier, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (07) :653-662
[36]   Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS):: a randomised non-inferiority trial [J].
Windecker, Stephan ;
Serruys, Patrick W. ;
Wandel, Simon ;
Buszman, Pawel ;
Trznadel, Stanislaw ;
Linke, Axel ;
Lenk, Karsten ;
Ischinger, Thomas ;
Klauss, Volker ;
Eberli, Franz ;
Corti, Roberto ;
Wijns, William ;
Morice, Marie Claude ;
di Mario, Carlo ;
Davies, Simon ;
van Geuns, Robert-Jan ;
Eerdmans, Pedro ;
van Es, Gerrit-Anne ;
Meier, Bernhard ;
Jueni, Peter .
LANCET, 2008, 372 (9644) :1163-1173